The DOI matches its Crossref record; 80 of the 81 references it cites were found in a registry or an index.
Hsp90 Regulates a von Hippel Lindau-independent Hypoxia-inducible Factor-1α-degradative Pathway
Open accessAbstract
HIF-1 alpha is a normally labile proangiogenic transcription factor that is stabilized and activated in hypoxia. Although the von Hippel Lindau (VHL) gene product, the ubiquitin ligase responsible for regulating HIF-1 alpha protein levels, efficiently targets HIF-1 alpha for rapid proteasome-dependent degradation under normoxia, HIF-1 alpha is resistant to the destabilizing effects of VHL under hypoxia. HIF-1 alpha also associates with the molecular chaperone Hsp90. To examine the role of Hsp90 in HIF-1 alpha function, we used renal carcinoma cell (RCC) lines that lack functional VHL and express stable HIF-1 alpha protein under normoxia. Geldanamycin (GA), an Hsp90 antagonist, promoted efficient ubiquitination and proteasome-mediated degradation of HIF-1 alpha in RCC in both normoxia and hypoxia. Furthermore, HIF-1 alpha point mutations that block VHL association did not protect HIF-1 alpha from GA-induced destabilization. Hsp90 antagonists also inhibited HIF-1 alpha transcriptional activity and dramatically reduced both hypoxia-induced accumulation of VEGF mRNA and hypoxia-dependent angiogenic activity. These findings demonstrate that disruption of Hsp90 function 1) promotes HIF-1 alpha degradation via a novel, oxygen-independent E3 ubiquitin ligase and 2) diminishes HIF-1 alpha transcriptional activity. Existence of an Hsp90-dependent pathway for elimination of HIF-1 alpha predicts that Hsp90 antagonists may be hypoxic cell sensitizers and possess antiangiogenic activity in vivo, thus extending the utility of these drugs as therapeutic anticancer agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, HSP90 inhibitors and histone acetylase inhibitors promote HIFα degradation in a pVHL-independent manner (Isaacs et al., 2002; Kong et al., 2006).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as Isaacs et al., 2002
In the citing paper
“It was reported that inhibitors of Hsp90 such as geldanamycin (GA) could nullify HIF-1α levels regardless of the availability of oxygen42.”
From HIF-1α pathway: role, regulation and intervention for cancer therapy (2015) · cites this paper as [42]
In the citing paper
“GA can induce proteasomal degradation of HIF-1α in a VHL-independent manner both under normoxic and hypoxic conditions (Isaacs et al., 2002).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Isaacs et al., 2002
In the citing paper
“Heat shock protein 90 (HSP90) stabilizes HIF-1α under hypoxia and in tumors, and pharmacological inhibition of HSP90 promotes HIF-1α destabilization [183].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [183]
Citations
Cites
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Semenza, G. L., & Wang, G. L. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.12.5447 · Cited by 2,617
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
Research works printed but not linked: 18
- Wiesener, 2001, Cancer Res., 61, 5215
- Zhong, 1999, Cancer Res., 59, 5830
- Birner, 2000, Cancer Res., 60, 4693
- Akakura, 2001, Cancer Res., 61, 6548
- Griffiths, 2002, Cancer Res., 62, 688
- Takahashi, 1994, Cancer Res., 54, 4233
- Wizigmann-Voos, 1995, Cancer Res., 55, 1358
- Whitesell, 1992, Cancer Res., 52, 1721
- Shaknovich, 1992, Mol. Cell. Biol., 12, 5059
- Hostein, 2001, Cancer Res., 61, 4003
- Nimmanapalli, 2001, Cancer Res., 61, 1799
- An, 2000, Cell Growth Differ., 11, 355
- Bonvini, 2002, Cancer Res., 62, 1559
- Adams, 1999, Cancer Res., 59, 2615
- Semenza, 1992, Mol. Cell. Biol., 12, 5447
- Hockel, 1999, Cancer Res., 59, 4525
- Mabjeesh, 2002, Cancer Res., 62, 2478
- Kruger, 2001, Clin. Cancer Res., 7, 1867
Cited by
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
“cgi?Q=hspca%20or%20hspcb%20not%20hspcal3&ORG=Hs">HSP90 , and the HSP90 inhibitor 17-allyl-aminogeldanamycin (17-AAG) induces HIF-1α degradation in a VHL-independent manne”
BackgroundOxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251
“For example, HSP90 inhibitors and histone acetylase inhibitors promote HIFa degradation in a pVHL-independent manner (Isaacs et al., 2002; Kong et al., 2006).”
BackgroundTargeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
HSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502
Hypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380
Metadata
- Authors
- Isaacs, J. S., Jung, Y.-J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., & Neckers, L. M.
- Affiliations
- National Institutes of Health (US)
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2002-08
- Volume
- 277
- Issue
- 33
- Pages
- 29936-29944
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2022471909
- Cited by
- 663
- References
- 81
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 10 · 2023: 19 · 2022: 22 · 2021: 32 · 2020: 19 · 2019: 20 · 2018: 19 · 2017: 20 · 2016: 22 · 2015: 30 · 2014: 31 · 2013: 27 · 2012: 41
- FWCI
- 13.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6667 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- HSP90, HIF-1α, VHL, hypoxia, protein degradation, geldanamycin, E3 ubiquitin ligase, proteasome, renal carcinoma, angiogenesis, vascular endothelial growth factor, anti-angiogenic therapy, hypoxic cell radiosensitizers
- MeSH terms
- Cysteine Endopeptidases, Hydrolysis, Ligases, Multienzyme Complexes, Transcription Factors, Transcription, Genetic, Tumor Cells, Cultured, Down-Regulation, HSP90 Heat-Shock Proteins, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases, Proteasome Endopeptidase Complex, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hsp90 Regulates a von Hippel Lindau-independent Hypoxia-inducible Factor-1α-degradative Pathway. https://app.cochat.ai/papers/10.1074/jbc.m204733200
- The paper
- Isaacs, J. S., Jung, Y.-J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., & Neckers, L. M. (2002). Hsp90 Regulates a von Hippel Lindau-independent Hypoxia-inducible Factor-1α-degradative Pathway. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.m204733200
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.